You just read:

Identification of new patient populations using validated companion diagnostic tests is a valuable strategy to help ensure payer acceptance of new premium priced targeted therapies and guide oncologists' treatment decisions.

News provided by

Decision Resources Group

Oct 05, 2016, 08:30 ET